BB BIOTECH AG
- WKN: A0NFN3
- ISIN: CH0038389992
- Land: Switzerland
Nachricht vom 23.10.2020 | 07:00
Biotech M&A picks up in the third quarter of 2020 - BB Biotech delivers a pleasing 9-month performance:
DGAP-News: BB BIOTECH AG
/ Key word(s): Interim Report
Media release as at October 23, 2020 Interim report of BB Biotech AG as at September 30, 2020 Biotech M&A picks up in the third quarter of 2020 - BB Biotech delivers a pleasing 9-month performance The Nasdaq biotechnology index consolidated in the third quarter (-0.8%) following a very strong second quarter. BB Biotech displayed a similar pattern. After surging 31.1% in CHF in the second quarter, its stock corrected in the third quarter, closing 3.4% lower in CHF and 4.3% lower in EUR. Net Asset Value (NAV) declined by 10.9% in CHF, 12.1% in EUR and 8.3% in USD in the third quarter. The resulting quarterly net loss was CHF 395 mn, compared to a net loss of CHF 382 mn for the same period in 2019. From a short-term perspective, the long-term realignment towards small- and mid-cap portfolio companies had a negative effect on its most recent quarterly performance. Biotech companies have captured the attention of the general public and the broader investment community since the outbreak of the pandemic. The entire healthcare industry has been working all-out to address the pandemic with projects under way across the technology spectrum, from diagnostics and devices to therapeutics and vaccines. While the Investment Management Team welcomes the speed and innovation the sector has displayed in its quest for solutions and the expectations of the development of effective SARS-CoV2 vaccines, news flow in other areas of interest, for example in oncology, is expected in the coming months. New portfolio position Milestones in Q3 2020 M&A activity and licensing agreements Outlook: better treatment options for acute infections expected Several portfolio companies will report key clinical trial results before the end of year:
Three drugs under regulatory review are expected to receive formal feedback prior to year-end: Relugolix from Myovant for the treatment of advanced prostate cancer; Lumasiran from Alnylam for the treatment of primary hyperoxaluria type 1; and Margetuximab from Macrogenics for the treatment of HER2-positive metastatic breast cancer. The Investment Management Team is actively monitoring the pandemic, the resulting healthcare and economic policy responses, and the many clinical trials currently under way. Based on its observations and findings to date, the team is confident that vaccine development programs and other action being taken to contain and overcome this challenging pathogen will ultimately be successful. Until that point is reached, it expects more effective therapeutics for active infections that ease the disease burden and reduce mortality rates will be developed. The interim report as at September 30, 2020 can be downloaded at www.bbbiotech.com. For further information: Investor Relations Media Relations TE Communications AG, St. Leonhard-Strasse 45, 9001 St. Gallen, Switzerland, tel. +41 79 423 22 28 Company profile Disclaimer Composition of BB Biotech's portfolio as at September 30, 2020
23.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
EQS News ID: | 1142531 |
End of News | DGAP News Service |
Interaktiv
Weblinks
Weitere News
-
19.02.21 07:00
BB Biotech AG publishes its 2020 annual report -
22.01.21 07:00
BB Biotech AG closes the 2020 fiscal year with ... -
22.01.21 07:00
BB BIOTECH AG: Vaccines leading the way out of ... -
16.12.20 09:40
BB BIOTECH AG: Moderna and its COVID-19 vaccin ... -
23.10.20 07:00
BB Biotech AG publishes its interim report
GBC-Fokusbox

International School Augsburg (ISA): Investment in den Rohstoff Bildung
Die in Gersthofen bei Augsburg ansässige International School Augsburg (ISA) plant als erste internationale Schule in Deutschland den Gang an die Börse und macht damit erstmals das Thema „Bildung“ unter ESG-Kriterien investierbar. Die ISA, an der derzeit rund 330 Schüler eingeschrieben sind, ist als internationale Schule Teil eines globalen Schulnetzwerkes, welches das in Deutschland anerkannte IB-Diploma als Hochschulzugangsberechtigung anbietet. Im Rahmen des geplanten Campus-Neubaus sollen die Kapazitäten erweitert und damit die hohe Nachfrage nach privaten Bildungsleistungen in Deutschland und in der Region erfüllt werden. GBC-Analyst Cosmin Filker hat mit dem ISA-Vorstand Marcus Wagner gesprochen.
Der AKTIONÄR News

05. März 12:30 Thomas Gebert Kolumne: Der „Kitchin“-Zyklus gibt vor, welche Aktien ...
05. März 12:10 Gaming-Ausrüster: Gaming rockt
05. März 12:06 Cashcows im Visier
05. März 11:15 Tesla-Bulle stößt seine Aktien ab!
05. März 11:09 TUI: So sehen Analysten die Kurszukunft des Reisekonzerns
News im Fokus

Linde Recognized by Bloomberg as a Leader in Gender Equality
04. März 2021, 11:59
Aktueller Webcast
Aktuelle Research-Studie

Media and Games Invest plc
Original-Research: Media and Games Invest plc (von First Berlin Equity Research GmbH): Buy
05. März 2021